Invivyd Inc. Closes $57.5 Million Public Offering, Fully Exercises Underwriter's Option for Additional Shares

Reuters

2025/08/23

Invivyd Inc. Closes $57.5 Million Public Offering, Fully Exercises Underwriter's Option for Additional Shares

Invivyd Inc. (Nasdaq: IVVD) has announced the successful closing of its underwritten public offering, raising approximately $57.5 million. The offering included 89,234,480 shares of common stock, with an additional option exercised by the underwriter for 14,423,076 shares, priced at $0.52 per share. Additionally, pre-funded warrants for 21,342,442 shares were offered at $0.5199 per warrant. Cantor Fitzgerald & Co. served as the sole book-running manager for the offering, which was led by RA Capital Management and Janus Henderson Investors, and saw participation from various healthcare-focused investors. Invivyd plans to allocate the net proceeds towards the development of the VYD2311 clinical program, research on respiratory syncytial virus (RSV) and measles, and efforts related to the Spike Protein Elimination and Recovery (SPEAR) Study Group, as well as for general corporate purposes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invivyd Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9516788-en) on August 22, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2561940675"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2561940675\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2561940675?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-23 00:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2561940675","market":"nz","top_or_hot":-1,"title":"Invivyd Inc. Closes $57.5 Million Public Offering, Fully Exercises Underwriter's Option for Additional Shares","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Invivyd Inc. Closes $57.5 Million Public Offering, Fully Exercises Underwriter's Option for Additional Shares\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Invivyd Inc. (Nasdaq: IVVD) has announced the successful closing of its underwritten public offering, raising approximately $57.5 million. The offering included 89,234,480 shares of common stock, with an additional option exercised by the underwriter for 14,423,076 shares, priced at $0.52 per share. Additionally, pre-funded warrants for 21,342,442 shares were offered at $0.5199 per warrant. Cantor Fitzgerald &amp; Co. served as the sole book-running manager for the offering, which was led by RA Capital Management and <a href=\"https://laohu8.com/S/JHG\">Janus Henderson</a> Investors, and saw participation from various healthcare-focused investors. Invivyd plans to allocate the net proceeds towards the development of the VYD2311 clinical program, research on respiratory syncytial virus (RSV) and measles, and efforts related to the Spike Protein Elimination and Recovery (SPEAR) Study Group, as well as for general corporate purposes.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invivyd Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9516788-en) on August 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Invivyd Inc. Closes $57.5 Million Public Offering, Fully Exercises Underwriter's Option for Additional Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInvivyd Inc. Closes $57.5 Million Public Offering, Fully Exercises Underwriter's Option for Additional Shares\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-23 00:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Invivyd Inc. Closes $57.5 Million Public Offering, Fully Exercises Underwriter's Option for Additional Shares\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Invivyd Inc. (Nasdaq: IVVD) has announced the successful closing of its underwritten public offering, raising approximately $57.5 million. The offering included 89,234,480 shares of common stock, with an additional option exercised by the underwriter for 14,423,076 shares, priced at $0.52 per share. Additionally, pre-funded warrants for 21,342,442 shares were offered at $0.5199 per warrant. Cantor Fitzgerald &amp; Co. served as the sole book-running manager for the offering, which was led by RA Capital Management and <a href=\"https://laohu8.com/S/JHG\">Janus Henderson</a> Investors, and saw participation from various healthcare-focused investors. Invivyd plans to allocate the net proceeds towards the development of the VYD2311 clinical program, research on respiratory syncytial virus (RSV) and measles, and efforts related to the Spike Protein Elimination and Recovery (SPEAR) Study Group, as well as for general corporate purposes.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invivyd Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9516788-en) on August 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BKPKM429.USD","symbol_name":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250822:nNDL1hlYHr:1","article_id":"2561940675","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2561940675","pubTimestamp":1755878462,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Invivyd Inc.  has announced the successful closing of its underwritten public offering, raising approximately $57.5 million. The offering included 89,234,480 shares of common stock, with an additional option exercised by the underwriter for 14,423,076 shares, priced at $0.52 per share. Additionally, pre-funded warrants for 21,342,442 shares were offered at $0.5199 per warrant. Cantor Fitzgerald & Co. served as the sole book-running manager for the offering, which was led by RA Capital Management and Janus Henderson Investors, and saw participation from various healthcare-focused investors. Invivyd plans to allocate the net proceeds towards the development of the VYD2311 clinical program, research on respiratory syncytial virus  and measles, and efforts related to the Spike Protein Elimination and Recovery  Study Group, as well as for general corporate purposes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","NDAQ":"纳斯达克OMX交易所","IVVD":"Invivyd, Inc.","BK4139":"生物科技","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU0054578231.USD":"BGF SYSTEMATIC SUSTAINABLE GLOBAL SMALLCAP \"A2\" (USD) ACC","BK4585":"ETF&股票定投概念","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4135":"资产管理与托管银行","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4539":"次新股","JHG":"骏利亨德森集团","BK4588":"碎股","BK4112":"金融交易所和数据"},"translate_title":"Invivyd Inc.完成5750万美元公开发行，完全行使承销商增发股票的选择权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"IVVD":0.9,"JHG":0.9},"content_text":"Invivyd Inc. Closes $57.5 Million Public Offering, Fully Exercises Underwriter's Option for Additional Shares\n    \n\n        Invivyd Inc. (Nasdaq: IVVD) has announced the successful closing of its underwritten public offering, raising approximately $57.5 million. The offering included 89,234,480 shares of common stock, with an additional option exercised by the underwriter for 14,423,076 shares, priced at $0.52 per share. Additionally, pre-funded warrants for 21,342,442 shares were offered at $0.5199 per warrant. Cantor Fitzgerald & Co. served as the sole book-running manager for the offering, which was led by RA Capital Management and Janus Henderson Investors, and saw participation from various healthcare-focused investors. Invivyd plans to allocate the net proceeds towards the development of the VYD2311 clinical program, research on respiratory syncytial virus (RSV) and measles, and efforts related to the Spike Protein Elimination and Recovery (SPEAR) Study Group, as well as for general corporate purposes.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invivyd Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9516788-en) on August 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}